Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Baxter
US Department of Justice
Johnson and Johnson
Deloitte
Healthtrust
Fish and Richardson
Chinese Patent Office
Federal Trade Commission
Moodys
Dow

Generated: October 18, 2017

DrugPatentWatch Database Preview

Details for Patent: 8,067,472

« Back to Dashboard

Which drugs does patent 8,067,472 protect, and when does it expire?


Patent 8,067,472 protects ZOLINZA and is included in one NDA.

This patent has eighty-seven patent family members in twenty-eight countries.

Summary for Patent: 8,067,472

Title:Methods of treating Hodgkin's and non-Hodgkin's lymphoma
Abstract: The present invention provides methods of selectively inducing terminal differentiation, cell growth arrest and/or apoptosis of neoplastic cells, and/or inhibiting histone deacetylase (HDAC) by administration of pharmaceutical compositions comprising potent HDAC inhibitors. The oral bioavailability of the active compounds in the pharmaceutical compositions of the present invention is surprisingly high. Moreover, the pharmaceutical compositions unexpectedly give rise to high, therapeutically effective blood levels of the active compounds over an extended period of time. The present invention further provides a safe, daily dosing regimen of these pharmaceutical compositions, which is easy to follow, and which results in a therapeutically effective amount of the HDAC inhibitors in vivo.
Inventor(s): Richon; Victoria M. (Rye, NY), Chiao; Judy H. (Berkeley Heights, NJ), Kelly; William Kevin (Scotch Plains, NJ), Miller; Thomas A. (Brookline, MA)
Assignee: Merck HDAC Research, LLC (Boston, MA) Sloan-Kettering Institute for Cancer Research (New York, NY)
Application Number:12/799,368
Patent Claim Types:
see list of patent claims
Use;

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use
Merck
ZOLINZA
vorinostat
CAPSULE;ORAL021991-001Oct 6, 2006RXYesYes► Subscribe► Subscribe TREATMENT OF CUTANEOUS MANIFESTATIONS IN PATIENTS WTIH CUTANEOUS T-CELL LYMPHOMA (CTCL)
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Non-Orange Book Patents for Patent: 8,067,472

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
7,652,069Polymorphs of suberoylanilide hydroxamic acid► Subscribe
7,148,257Methods of treating mesothelioma with suberoylanilide hydroxamic acid► Subscribe
7,851,509Polymorphs of suberoylanilide hydroxamic acid► Subscribe
8,101,663Polymorphs of suberoylanilide hydroxamic acid► Subscribe
7,399,787Methods of treating cancer with HDAC inhibitors► Subscribe
7,456,219Polymorphs of suberoylanilide hydroxamic acid► Subscribe
7,732,490Methods of treating cancer► Subscribe
7,375,137Methods of treating cancer with HDAC inhibitors► Subscribe
7,847,122Polymorphs of suberoylanilide hydroxamic acid► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Patent: 8,067,472

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Austria462426► Subscribe
Australia2003213684► Subscribe
Australia2004266169► Subscribe
Australia2004283717► Subscribe
Australia2008246251► Subscribe
Australia2009201668► Subscribe
Brazil0308250► Subscribe
BrazilPI0413826► Subscribe
Canada2478094► Subscribe
Canada2535806► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the database preview and plans and pricing

Serving leading biopharmaceutical companies globally:

Cantor Fitzgerald
Mallinckrodt
Julphar
US Department of Justice
Fuji
Harvard Business School
Daiichi Sankyo
Novartis
Teva
Moodys

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot